SR-1375 is under clinical development by Shanghai SIMR Biotech and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL).

R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.